Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
FTC wants more information on Novo-Catalent deal in antitrust review
The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.